Bluesight Revenue and Competitors
Employee Data
- Bluesight has 142 Employees.
- Bluesight grew their employee count by 1% last year.
Bluesight's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
2 | Co-Founder | Reveal Email/Phone |
3 | VP Sales and Account Management | Reveal Email/Phone |
4 | VP Sales | Reveal Email/Phone |
Bluesight Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 68 | 39% | N/A | N/A |
#2 | $1.7M | 52 | -4% | N/A | N/A |
#3 | N/A | 25 | 213% | N/A | N/A |
#4 | N/A | 41 | 37% | N/A | N/A |
#5 | N/A | 24 | 33% | N/A | N/A |
#6 | N/A | 82 | 64% | N/A | N/A |
#7 | N/A | 31 | 35% | N/A | N/A |
#8 | N/A | 57 | 4% | N/A | N/A |
#9 | $35M | 11 | 10% | N/A | N/A |
#10 | N/A | 9 | 50% | N/A | N/A |
What Is Bluesight?
Bluesight solves supply chain inefficiencies and reduces risk by providing actionable analytics for every step of the medication lifecycle. Through our suite of Medication Intelligence™ solutions, Bluesight brings simplicity, visibility, and predictability to the complex world of medication management. To date, more than 1,000 U.S. and Canadian hospitals utilize Bluesight solutions to optimize their hospital’s efficiency. Bluesight focuses on providing comprehensive, item-level data that empowers providers to make informed, accurate decisions. These solutions include RFID-enabled inventory management, controlled substance diversion prevention software and medication purchasing optimization. To learn more about Bluesight ’s suite of Medication Intelligence solutions, visit us at bluesight.com.
keywords:N/AN/A
Total Funding
142
Number of Employees
N/A
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $28.1M | 142 | -5% | N/A |
#2 | $7.5M | 142 | 2% | N/A |
#3 | $25.5M | 142 | 7% | N/A |
#4 | $23M | 144 | 4% | N/A |
#5 | $35M | 145 | 4% | N/A |